STOCK TITAN

Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
UCB has awarded 15 scholarships to individuals affected by myasthenia gravis (MG) in the U.S. through its inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship program. The recipients include both people living with MG and caregivers, with one-third being high school seniors and others pursuing undergraduate, graduate degrees, or certification programs. The selection committee comprised medical professionals and people impacted by MG. Kim Moran, SVP & Head of U.S. Rare Diseases at UCB, announced that the scholarship program will continue into 2026. The initiative demonstrates UCB's commitment to supporting the rare disease community beyond medical treatment by helping recipients manage educational costs and advance their career goals.
UCB ha assegnato 15 borse di studio a persone colpite da miastenia grave (MG) negli Stati Uniti attraverso il suo primo programma di borse di studio 2025 UCB U.S. Myasthenia Gravis Scholarship. I beneficiari includono sia persone affette da MG che i loro caregiver, con un terzo di loro studenti dell'ultimo anno di scuola superiore e altri impegnati in corsi di laurea triennale, magistrale o programmi di certificazione. La commissione di selezione era composta da professionisti medici e persone coinvolte dalla MG. Kim Moran, SVP e Responsabile delle Malattie Rare negli USA per UCB, ha annunciato che il programma di borse di studio continuerà nel 2026. Questa iniziativa dimostra l'impegno di UCB nel supportare la comunità delle malattie rare oltre il trattamento medico, aiutando i beneficiari a gestire i costi dell'istruzione e a perseguire i loro obiettivi professionali.
UCB ha otorgado 15 becas a personas afectadas por miastenia gravis (MG) en Estados Unidos mediante su programa inaugural de becas 2025 UCB U.S. Myasthenia Gravis Scholarship. Los beneficiarios incluyen tanto a personas que viven con MG como a cuidadores, con un tercio siendo estudiantes de último año de secundaria y otros cursando estudios universitarios, de posgrado o programas de certificación. El comité de selección estuvo formado por profesionales médicos y personas afectadas por MG. Kim Moran, vicepresidente senior y jefe de Enfermedades Raras en EE.UU. de UCB, anunció que el programa de becas continuará en 2026. Esta iniciativa demuestra el compromiso de UCB de apoyar a la comunidad de enfermedades raras más allá del tratamiento médico, ayudando a los beneficiarios a cubrir los costos educativos y avanzar en sus metas profesionales.
UCB는 미국 내 중증 근무력증(MG) 환자들을 위해 2025년 첫 UCB 미국 중증 근무력증 장학금 프로그램을 통해 15명의 장학생을 선정했습니다. 수혜자는 MG 환자와 돌보미를 포함하며, 3분의 1은 고등학교 졸업 예정자이고 나머지는 학부, 대학원 또는 자격증 프로그램을 이수 중입니다. 선정 위원회는 의료 전문가와 MG 영향을 받은 사람들로 구성되었습니다. UCB 미국 희귀질환 담당 수석 부사장 킴 모란은 장학금 프로그램이 2026년에도 계속될 것이라고 발표했습니다. 이 이니셔티브는 의료 치료를 넘어 희귀질환 커뮤니티를 지원하고, 수혜자들이 교육비를 관리하며 경력 목표를 달성할 수 있도록 돕는 UCB의 의지를 보여줍니다.
UCB a attribué 15 bourses d'études à des personnes touchées par la myasthénie grave (MG) aux États-Unis dans le cadre de son tout premier programme de bourses 2025 UCB U.S. Myasthenia Gravis Scholarship. Les bénéficiaires comprennent à la fois des personnes vivant avec la MG et des aidants, un tiers d’entre eux étant des lycéens en terminale, les autres poursuivant des études de premier cycle, de deuxième cycle ou des programmes de certification. Le comité de sélection était composé de professionnels médicaux et de personnes concernées par la MG. Kim Moran, vice-présidente senior et responsable des maladies rares aux États-Unis chez UCB, a annoncé que le programme de bourses se poursuivra en 2026. Cette initiative témoigne de l’engagement d’UCB à soutenir la communauté des maladies rares au-delà du traitement médical, en aidant les bénéficiaires à gérer les coûts liés à l’éducation et à faire avancer leurs objectifs professionnels.
UCB hat im Rahmen seines ersten 2025 UCB U.S. Myasthenia Gravis Stipendienprogramms 15 Stipendien an Personen in den USA vergeben, die von Myasthenia Gravis (MG) betroffen sind. Zu den Empfängern gehören sowohl Menschen mit MG als auch Pflegepersonen, wobei ein Drittel Abiturienten sind und die anderen ein Bachelor-, Masterstudium oder Zertifikatsprogramme absolvieren. Das Auswahlkomitee bestand aus medizinischen Fachkräften und von MG betroffenen Personen. Kim Moran, Senior Vice President und Leiter der seltenen Krankheiten in den USA bei UCB, gab bekannt, dass das Stipendienprogramm auch 2026 fortgesetzt wird. Diese Initiative zeigt UCBs Engagement, die Gemeinschaft der seltenen Krankheiten über die medizinische Behandlung hinaus zu unterstützen, indem sie den Empfängern hilft, Bildungskosten zu bewältigen und ihre beruflichen Ziele zu verfolgen.
Positive
  • None.
Negative
  • None.

ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship exemplifies UCB's dedication to supporting the rare disease community that goes beyond medicine. Living with or supporting a loved one impacted by this rare disease can be challenging. This scholarship program can help ease the costs associated with education and allow recipients to gain new skills to further their career goals.

This year's 15 scholarship recipients are a diverse group of passionate advocates including people living with MG or caregiving for a parent living with MG. Of the awardees, one-third are graduating high school seniors, with the remainder planning to pursue undergraduate or graduate degrees and certification programs. 

"We are so honored to have received such outstanding applications from all over the country. UCB is inspired by the stories not only of the 15 recipients, but of all the applicants. UCB is driven to take meaningful action to meet their unmet needs," said Kim Moran, SVP & Head, U.S. Rare Diseases, UCB. "That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026."

"Financially, I face significant challenges as I juggle the costs of school, living expenses, and medical treatments. With this assistance, I can continue to pursue my dream of becoming a nurse and use my experiences to inspire and support others," said Katy M., one of the UCB Myasthenia Gravis Scholarship recipients.

The selection committee for the UCB Myasthenia Gravis Scholarship was made up of people impacted by myasthenia gravis and medical professionals specializing in neuromuscular diseases.

"Serving on the UCB Scholarship Committee was a deeply emotional experience," said Leila Darki, MD, from the University of Southern California. "Each personal story of someone living with myasthenia gravis reflected such resilience and courage. It truly touched my heart. This experience reminded me why our work matters and left me truly inspired."

"It was a meaningful experience serving on the UCB Scholarship Committee. I was genuinely moved by how much these applicants have accomplished despite the obstacles they've faced," said Jerrica Farrias, MS, APRN, from the University of South Florida. "Their determination speaks for itself, and I felt honored to help recognize their hard work."

Congratulations to this year's recipients of the 2025 UCB Myasthenia Gravis Scholarship:

Drew C. – Findlay, Ohio
Deanna C. – Beverly, Massachusetts
Zeña D. – Lake Forest, California
Joseph L. – Seabrook, New Hampshire
Brylee M. – Excelsior Springs, Missouri
Katy M. – Batesville, Indiana
Noelle P. – Pinson, Alabama
Lauren R. – Fallbrook, California
Joleen R. – Clearwater, Florida
Darrius S. – Avon, Indiana
Antonina S. – Katy, Texas
Deric S. – Wetumpka, Alabama
Note: Recipients' names are included with their permission. Some recipients opted not to have their names included in this announcement.

The UCB Myasthenia Gravis Scholarship™ is a trademark of the UCB Group of Companies.

©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-DA-2500185

For further information, contact UCB:

U.S. Rare Disease Communications
Daphne Teo
Daphne.teo@ucb.com
T +1-770-880-7655

About UCB 

UCB, Brussels, Belgium (www.ucb.com), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 6.15 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About the UCB Myasthenia Gravis Scholarship™

The UCB Myasthenia Gravis Scholarship offers educational scholarships to people living with myasthenia gravis and their immediate family members who are pursuing further education, whether they are continuing their education or aiming to gain new career skills. The scholarship can be used for an associate's, undergraduate, graduate degree, or specialty/trade school certificate. Scholarship requirements and limitations apply. For more information, please visit www.ucbmgscholarship.com.

Forward looking statements 

This press release contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inaugural-2025-ucb-us-myasthenia-gravis-scholarship-grants-15-scholarships-to-people-impacted-by-myasthenia-gravis-in-the-us-302483824.html

SOURCE UCB

FAQ

What is the UCB U.S. Myasthenia Gravis Scholarship program?

It is a scholarship program by UCB that awards educational funding to people impacted by myasthenia gravis, including both patients and caregivers, to help with educational costs and career advancement.

How many scholarships did UCB (UCBJY) award in 2025?

UCB awarded 15 scholarships in 2025 through its inaugural U.S. Myasthenia Gravis Scholarship program.

Who was eligible for the 2025 UCB Myasthenia Gravis Scholarship?

The scholarship was available to people living with myasthenia gravis and those caregiving for parents with MG, including high school seniors, undergraduate and graduate students, and those pursuing certification programs.

Will UCB continue the Myasthenia Gravis Scholarship program?

Yes, UCB has announced that the scholarship program will continue into 2026.

Who served on the UCB Myasthenia Gravis Scholarship selection committee?

The selection committee consisted of people impacted by myasthenia gravis and medical professionals specializing in neuromuscular diseases.
Ucb S A

OTC:UCBJY

UCBJY Rankings

UCBJY Latest News

UCBJY Stock Data

37.35B
380.08M
0%
Biotechnology
Healthcare
Link
Belgium
Brussels